Results 251 to 260 of about 41,938 (307)

Comparative efficacy and safety of bispecific antibody teclistamab versus CAR-T cell therapies in relapsed/refractory multiple myeloma: a retrospective evaluation. [PDF]

Am J Cancer Res
Guo Y, Shi R.
europepmc   +1 more source

Bispecific antibody targeting shared indel-derived neoantigen of APC. [PDF]

Front Immunol
Effenberger C, Wu X, Zhao P, Matsumoto S, Nakamura Y, Kiyotani K.   +5 more
europepmc   +1 more source

Systematic review and meta-analysis: CAR-T vs bispecific antibody as third or later-line therapy for follicular lymphoma. [PDF]

Blood Cancer J
Ng LCK, Lee XH, Tan YC, Wong KL, Chow JCY, Ling VWT, Thong EWS, Chan EHL, Chan WL, Samuel M, Poon MLM.   +10 more
europepmc   +1 more source

Successful Treatment of Diffuse Large B-Cell Lymphoma and Antisynthetase Syndrome with Bispecific Antibody Glofitamab. [PDF]

Cancer Manag Res
Wei C, Zhang M, Zhao D, Zhang W, Zhang Y.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Bispecific Antibodies for the Treatment of Neuroblastoma

SSRN Electronic Journal, 2022
Bispecific antibodies (BsAb) are a new generation of antibody-based therapy, conveying artificial specificity to polyclonal T cells or radiohaptens. These drugs have been successfully implemented to cure hematologic malignancies and are under clinical investigation for solid tumors including HRNB.
Madelyn, Espinosa-Cotton, Nai-Kong V, Cheung   +1 more
openaire   +2 more sources

Engineering bispecific antibodies

Current Opinion in Biotechnology, 1993
Bispecific antibodies have immense potential as reagents and in medicine. Until recently, they were made by combining monoclonal antibodies of two different specificities in vitro, or by fusion of the corresponding hybridomas. Protein engineering now offers the chance to construct a range of small 'designer' bispecific antibodies using antibody ...
P, Holliger, G, Winter
openaire   +2 more sources

Bispecific Antibodies in Lymphoma

International Reviews of Immunology, 1993
info:eu-repo/semantics ...
Brissinck, J, Demanet, Christian, Moser, Muriel, Leo, Oberdan, Thielemans, Kris   +4 more
openaire   +3 more sources

A revival of bispecific antibodies

Trends in Biotechnology, 2004
Bispecific antibodies usually do not occur in nature but are constructed by recombinant DNA or cell-fusion technologies. Most are designed to recruit cytotoxic effector cells of the immune system effectively against pathogenic target cells. This complex task explains why, after more than 15 years of extensive research, many different formats of ...
Peter, Kufer, Ralf, Lutterbüse, Patrick A, Baeuerle   +2 more
openaire   +2 more sources

Production of Bispecific Antibodies

Current Protocols in Immunology, 1995
AbstractBispecific antibodies (bsAbs) contain two different binding specificities within a single molecule and can specifically bind two different molecules together. BsAbs can be produced by chemically cross‐linking purified antibodies or Fab fragments with reducible disulfide bonds or nonreducible thioether bonds, both of which are described in this ...
David M, Segal, Bert J E G, Bast
openaire   +2 more sources

Bispecific antibodies for the treatment of hemophilia A

Expert Opinion on Biological Therapy, 2021
Emicizumab is a bispecific antibody exerting cofactor function of FVIIIa irrespective of the presence of FVIII inhibitors. Long-term data of phase 1/2 and phase 3 studies have been accumulated. Various questions such as indicated patients, ITI, application to PUPs, hemostatic treatment including surgeries, and emicizumab-related morbidity remain to be ...
openaire   +2 more sources